pages:
-
: Network for Cardiothoracic Surgical Investigations in Cardiovascular Medicine: ¿Long-Term Follow-Up for Participants of MMR and SMR Trials
-
[DP-1111-02CT] A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard
-
[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)
-
[Exhibit] Memories from the Korean War: Personal Accounts, Photos, and Letters [Conference] East Asian Collection at Duke University Libraries: Past, Present, and Future
-
[In] Cognitio Veritas: Neural and Cognitive First Principles as Ground Truth for Social Simulation
Research Grant
-
[MK-6482-016] Pembrolizumab plus lenvatinib and belzutifan for specified solid tumors
-
[NuTide:302] A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment
-
\Uscular Effect On Mandibular Movements In Primates
Research Grant
-
A 12-month study to investigate the efficacy, safety and pharmacokinetics of a monthly dosing regimen of ranibizumab (0.5 mg) in combination with pegpleranib (1.5mg), compared to monthly raranibizumab (0.5 mg)
monotherapy, in patients with nAMD
Research Grant
-
A 12-month, multi-center, open-label study to investigate the safety of pegpleranib (1.5 mg) in combination with anti-VEGF agents, ranibizumab (0.5 mg) or aflibercept (2 mg), in Japanese patients with neovascular age-related macular degeneration
Research Grant
-
A 12-week parallel group, randomized, placebo-controlled, double-blinded, multi-center study to evaluate efficacy and safety of 2 concentrations of SAF312 eye drops (5 mg/ml and 15 mg/ml) used twice-daily in the treatment of postoperative corneal
-
A 15 Week, Phase 2, Double Blind, Randomized, Placebo-Controlled, Dose Ranging Study to Investigate the Efficacy, Safety and Tolerability of PF 06649751 in Subjects with Motor Fluctuations due to PD
-
A 24-week, double-blind, randomized, parallel-group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF)
-
A 3D ex vivo orthotopic xenograft screening platform to identify radiosensitization targets and druggability in glioma
Research Grant
-
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate hydrochloride] in Subjects with Parkinson's Disease and Excessive Sleep
Research Grant
-
A 400 MHZ NMR Spectrometer for Chemical Research
-
A 48 Week Phase II, Randomized, Open-Label, Multicenter, Study to Evaluate the Efficacy and Safety of Two (2) EYS606 (pEYS606 administered by injection and electrotransfer to the ciliary muscle) Treatment Regimens in Patients with CNIU
Research Grant
-
A 52-week multicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-related macular degeneration.
Research Grant
-
A 52-week, double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of Nintedanib, 150 mg twice daily, in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
-
A 6-month parallel group, randomized, investigator-blind, placebo-controlled, multicenter proof of concept trial comparing the efficacy of E25 to that of placebo in the treatment of moderate to severe atopic dermatitis in subjects 6-16
Fellowships, Supported Research, and Other Grants
-
A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)
-
A 6-week, Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline versus Placebo in Subjects 6 to 12 Years of Age with Attention Deficit Hyperactivity Disorder (ADHD)
-
A 6-Week, Randomized, Multicenter, Double-Blind, Parallel, Flexed- and Fixed-dose Study of MG01CI (Metadoxine Extended-Release) 700 Mg and 1400 Mg Compared with Placebo in Adults and Adolescents with Fragile X Syndrome
-
A 72-Week, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study in Subjects with Mild Cognitive Impairment due to Alzheimer's Disease (AD) (Stage 3 AD) to Evaluate the Effect on Cognitive and Functional Impairment, Safety, and Tolerabilit
-
A Background Paper on a Hidden Harvests 2 Study
Research Grant
-
A Biochemical Analysis Of Pre-Mrna Splicing
Research Grant
-
A Biomarker Study of the APEX-AMI and SOLSTICE Trial Populations
Research Grant
-
A Biomarker-Based Trial of Plasmalogen Repletion in MCI/AD
Research Grant
-
A biomechanical comparison of suture anchor fixation with and without suture tape augmentation
Research Grant
-
A Biomechanical Evaluation of Nitinol Memory Staple Augmentation for Internal Fixation of Transverse Humeral Shaft Fractures
Research Grant
pages: